Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Wright Reports
|
$391.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: GlobalData
|
$125.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Sichuan Kelun Pharmaceutical Co Ltd Announces Merger of Subsidiaries
Sichuan Kelun Pharmaceutical Co Ltd announced its 80%-owned subsidiary, a Guizhou-based pharmaceutical company (Subsidiary A), will merge the Company's wholly owned subsidiary, a Guzihou-based technology company (Subsidiary B), with Subsidiary B to be dissolved and Subsidiary A to survive.
Latest Developments for Sichuan Kelun Pharmaceutical Co Ltd
Latest Key Developments in Pharmaceuticals
- Valeant Pharmaceuticals International Inc Near Deal To Acquire Bausch & Lomb From Warburg Pincus LLC-Reuters
- Valeant Pharmaceuticals International Inc Near Deal To Acquire Bausch & Lomb-Reuters
- Astec LifeSciences Ltd Recommends Dividend; Announces Appointment Of Statutory Auditors
- J B Chemicals and Pharmaceuticals Ltd Recommends Dividend
- Share this
- Link this
- Digg this
Follow Reuters